30 results on '"Southey, M"'
Search Results
2. Mould-sensitized adults have lower Th2 cytokines and a higher prevalence of asthma than those sensitized to other aeroallergens.
- Author
-
Matheson, M. C., Reece, J. C., Kandane‐Rathnayake, R. K., Tang, M. L. K., Simpson, J. A., Feather, I. H., Southey, M. C., Tsimiklis, H., Hopper, J. L., Morrison, S. C., Giles, G. G., Walters, E. H., and Dharmage, S. C.
- Subjects
ASTHMA risk factors ,ALLERGY diagnosis ,ALLERGY treatment ,DISEASE prevalence ,BLOOD serum analysis ,T helper cells ,CYTOKINES ,DISEASES in adults - Abstract
Background Evidence suggests that specific allergen sensitizations are associated with different allergic diseases which may reflect different underlying immune profiles. We aimed to examine the cytokine profiles of individuals sensitized to eight common aeroallergens. Methods We used data from the Tasmanian Longitudinal Health Study a population-based cohort study of 45-year-olds. Serum cytokines ( IL-4, IL-5, IL-6, IL-8, IL-10, TNF-α) were measured in 1157 subjects using the LINCOplex assays. Participants underwent skin prick testing for house dust mite, cat, grasses and moulds. Multivariable linear regression was used to compare serum cytokine levels between sensitized and nonatopic subjects. Results The prevalence of allergic sensitization to any aeroallergen was 51% (95% CI 47-54). Being sensitized to any aeroallergen was strongly associated with current asthma ( OR = 3.7, 95% CI 2.6-5.3), and being sensitized to any moulds was associated with a very high risk of current asthma (OR = 6.40, 95% CI 4.06-10.1). The geometric mean ( GM) levels of Th2 cytokines ( IL-4, IL-5 and IL-6) for adults sensitized to Cladosporium were significantly lower than the levels for nonatopic individuals ( IL-4 ratio of GMs = 0.25, 95% CI 0.10-0.62, P = 0.003; IL-5 GM = 0.55, 95% CI 0.30-0.99, P = 0.05; and IL-6 GM = 0.50, 95% CI 0.24-1.07, P = 0.07). Individuals sensitized to other aeroallergens all showed elevated Th2 cytokine levels. Conclusion Our study is the first large population-based study to demonstrate reduced Th2 cytokines levels in people sensitized to mould. Underlying biological mechanisms driving allergic inflammatory responses in adults sensitized to moulds may differ from those sensitized to other aeroallergens. These findings suggest that it may be necessary to tailor treatments in individuals sensitized to moulds compared with other aeroallergens in order to optimize outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
3. Evaluation of water displacement energetics in protein binding sites with grid cell theory.
- Author
-
Gerogiokas, G., Southey, M. W. Y., Mazanetz, M. P., Hefeitz, A., Bodkin, M., Law, R. J., and Michel, J.
- Abstract
Excess free energies, enthalpies and entropies of water in protein binding sites were computed via classical simulations and Grid Cell Theory (GCT) analyses for three pairs of congeneric ligands in complex with the proteins scytalone dehydratase, p38α MAP kinase and EGFR kinase respectively. Comparative analysis is of interest since the binding modes for each ligand pair differ in the displacement of one binding site water molecule, but significant variations in relative binding affinities are observed. Protocols that vary in their use of restraints on protein and ligand atoms were compared to determine the influence of protein–ligand flexibility on computed water structure and energetics, and to assess protocols for routine analyses of protein–ligand complexes. The GCT-derived binding affinities correctly reproduce experimental trends, but the magnitude of the predicted changes in binding affinities is exaggerated with respect to results from a previous Monte Carlo Free Energy Perturbation study. Breakdown of the GCT water free energies into enthalpic and entropic components indicates that enthalpy changes dominate the observed variations in energetics. In EGFR kinase GCT analyses revealed that replacement of a pyrimidine by a cyanopyridine perturbs water energetics up three hydration shells away from the ligand. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
4. Effects of Tamoxifen and oestrogen on histology and radiographic density in high and low mammographic density human breast tissues maintained in murine tissue engineering chambers.
- Author
-
Chew, G., Huo, C., Huang, D., Blick, T., Hill, P., Cawson, J., Frazer, H., Southey, M., Hopper, J., Britt, K., Henderson, M., Haviv, I., and Thompson, E.
- Abstract
Mammographic density (MD) is a strong risk factor for breast cancer. It is altered by exogenous endocrine treatments, including hormone replacement therapy and Tamoxifen. Such agents also modify breast cancer (BC) risk. However, the biomolecular basis of how systemic endocrine therapy modifies MD and MD-associated BC risk is poorly understood. This study aims to determine whether our xenograft biochamber model can be used to study the effectiveness of therapies aimed at modulating MD, by examine the effects of Tamoxifen and oestrogen on histologic and radiographic changes in high and low MD tissues maintained within the biochamber model. High and low MD human tissues were precisely sampled under radiographic guidance from prophylactic mastectomy fresh specimens of high-risk women, then inserted into separate vascularized murine biochambers. The murine hosts were concurrently implanted with Tamoxifen, oestrogen or placebo pellets, and the high and low MD biochamber tissues maintained in the murine host environment for 3 months, before the high and low MD biochamber tissues were harvested for histologic and radiographic analyses. The radiographic density of high MD tissue maintained in murine biochambers was decreased in Tamoxifen-treated mice compared to oestrogen-treated mice ( p = 0.02). Tamoxifen treatment of high MD tissue in SCID mice led to a decrease in stromal ( p = 0.009), and an increase in adipose ( p = 0.023) percent areas, compared to placebo-treated mice. No histologic or radiographic differences were observed in low MD biochamber tissue with any treatment. High MD biochamber tissues maintained in mice implanted with Tamoxifen, oestrogen or placebo pellets had dynamic and measurable histologic compositional and radiographic changes. This further validates the dynamic nature of the MD xenograft model, and suggests the biochamber model may be useful for assessing the underlying molecular pathways of Tamoxifen-reduced MD, and in testing of other pharmacologic interventions in a preclinical model of high MD. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
5. Reproductive risk factors and oestrogen/progesterone receptor-negative breast cancer in the Breast Cancer Family Registry.
- Author
-
Work, M E, John, E M, Andrulis, I L, Knight, J A, Liao, Y, Mulligan, A M, Southey, M C, Giles, G G, Dite, G S, Apicella, C, Hibshoosh, H, Hopper, J L, and Terry, M B
- Subjects
ESTROGEN receptors ,PROGESTERONE receptors ,BREAST cancer ,BREASTFEEDING ,ETHNICITY ,ORAL contraceptives - Abstract
Background:Oestrogen receptor (ER)- and progesterone receptor (PR)-negative (ER−PR−) breast cancer is associated with poorer prognosis compared with other breast cancer subtypes. High parity has been associated with an increased risk of ER−PR− cancer, but emerging evidence suggests that breastfeeding may reduce this risk. Whether this potential breastfeeding benefit extends to women at high risk of breast cancer remains critical to understand for prevention.Methods:Using population-based ascertained cases (n=4011) and controls (2997) from the Breast Cancer Family Registry, we examined reproductive risk factors in relation to ER and PR status.Results:High parity (3 live births) without breastfeeding was positively associated only with ER−PR− tumours (odds ratio (OR)=1.57, 95% confidence interval (CI), 1.10-2.24); there was no association with parity in women who breastfed (OR=0.93, 95% CI 0.71-1.22). Across all race/ethnicities, associations for ER−PR− cancer were higher among women who did not breastfeed than among women who did. Oral contraceptive (OC) use before 1975 was associated with an increased risk of ER−PR− cancer only (OR=1.32, 95% CI 1.04-1.67). For women who began OC use in 1975 or later there was no increased risk.Conclusions:Our findings support that there are modifiable factors for ER−PR− breast cancer and that breastfeeding in particular may mitigate the increased risk of ER−PR− cancers seen from multiparity. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
6. Prospective validation of the breast cancer risk prediction model BOADICEA and a batch-mode version BOADICEACentre.
- Author
-
MacInnis, R J, Bickerstaffe, A, Apicella, C, Dite, G S, Dowty, J G, Aujard, K, Phillips, K-A, Weideman, P, Lee, A, Terry, M B, Giles, G G, Southey, M C, Antoniou, A C, and Hopper, J L
- Subjects
ALGORITHMS ,BREAST cancer risk factors ,CALIBRATION ,RECEIVER operating characteristic curves ,CONFIDENCE intervals ,INDEX use studies ,CANCER in women ,WOMEN ,CANCER risk factors - Abstract
Background:Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm (BOADICEA) is a risk prediction algorithm that can be used to compute estimates of age-specific risk of breast cancer. It is uncertain whether BOADICEA performs adequately for populations outside the United Kingdom.Methods:Using a batch mode version of BOADICEA that we developed (BOADICEACentre), we calculated the cumulative 10-year invasive breast cancer risk for 4176 Australian women of European ancestry unaffected at baseline from 1601 case and control families in the Australian Breast Cancer Family Registry. Based on 115 incident breast cancers, we investigated calibration, discrimination (using receiver-operating characteristic (ROC) curves) and accuracy at the individual level.Results:The ratio of expected to observed number of breast cancers was 0.92 (95% confidence interval (CI) 0.76-1.10). The E/O ratios by subgroups of the participant's relationship to the index case and by the reported number of affected relatives ranged between 0.83 and 0.98 and all 95% CIs included 1.00. The area under the ROC curve was 0.70 (95% CI 0.66-0.75) and there was no evidence of systematic under- or over-dispersion (P=0.2).Conclusion:BOADICEA is well calibrated for Australian women, and had good discrimination and accuracy at the individual level. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
7. Dynamic changes in high and low mammographic density human breast tissues maintained in murine tissue engineering chambers during various murine peripartum states and over time.
- Author
-
Chew, G., Huang, D., Huo, C., Blick, T., Hill, P., Cawson, J., Frazer, H., Southey, M., Hopper, J., Henderson, M., Haviv, I., and Thompson, E.
- Abstract
Mammographic density (MD) is a strong heritable risk factor for breast cancer, and may decrease with increasing parity. However, the biomolecular basis for MD-associated breast cancer remains unclear, and systemic hormonal effects on MD-associated risk is poorly understood. This study assessed the effect of murine peripartum states on high and low MD tissue maintained in a xenograft model of human MD. Method High and low MD human breast tissues were precisely sampled under radiographic guidance from prophylactic mastectomy specimens of women. The high and low MD tissues were maintained in separate vascularised biochambers in nulliparous or pregnant SCID mice for 4 weeks, or mice undergoing postpartum involution or lactation for three additional weeks. High and low MD biochamber material was harvested for histologic and radiographic comparisons during various murine peripartum states. High and low MD biochamber tissues in nulliparous mice were harvested at different timepoints for histologic and radiographic comparisons. Results High MD biochamber tissues had decreased stromal ( p = 0.0027), increased adipose ( p = 0.0003) and a trend to increased glandular tissue areas ( p = 0.076) after murine postpartum involution. Stromal areas decreased ( p = 0.042), while glandular ( p = 0.001) and adipose areas ( p = 0.009) increased in high MD biochamber tissues during lactation. A difference in radiographic density was observed in high ( p = 0.0021) or low MD biochamber tissues ( p = 0.004) between nulliparous, pregnant and involution groups. No differences in tissue composition were observed in high or low MD biochamber tissues maintained for different durations, although radiographic density increased over time. Conclusion High MD biochamber tissues had measurable histologic changes after postpartum involution or lactation. Alterations in radiographic density occurred in biochamber tissues between different peripartum states and over time. These findings demonstrate the dynamic nature of the human MD xenograft model, providing a platform for studying the biomolecular basis of MD-associated cancer risk. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
8. Evaluation of variation in the phosphoinositide-3-kinase catalytic subunit alpha oncogene and breast cancer risk.
- Author
-
Stevens, K N, Garcia-Closas, M, Fredericksen, Z, Kosel, M, Pankratz, V S, Hopper, J L, Dite, G S, Apicella, C, Southey, M C, Schmidt, M K, Broeks, A, Van 't Veer, L J, Tollenaar, R A E M, Fasching, P A, Beckmann, M W, Hein, A, Ekici, A B, Johnson, N, Peto, J, and dos Santos Silva, I
- Subjects
BREAST cancer ,PHOSPHOINOSITIDES ,TUMORS ,LYMPH nodes ,METASTASIS ,GENETIC markers ,BREAST tumors ,COMPARATIVE studies ,DISEASE susceptibility ,GENETICS ,RESEARCH methodology ,MEDICAL cooperation ,PHOSPHOTRANSFERASES ,RESEARCH ,EVALUATION research ,CASE-control method - Abstract
Background: Somatic mutations in phosphoinositide-3-kinase catalytic subunit alpha (PIK3CA) are frequent in breast tumours and have been associated with oestrogen receptor (ER) expression, human epidermal growth factor receptor-2 overexpression, lymph node metastasis and poor survival. The goal of this study was to evaluate the association between inherited variation in this oncogene and risk of breast cancer.Methods: A single-nucleotide polymorphism from the PIK3CA locus that was associated with breast cancer in a study of Caucasian breast cancer cases and controls from the Mayo Clinic (MCBCS) was genotyped in 5436 cases and 5280 controls from the Cancer Genetic Markers of Susceptibility (CGEMS) study and in 30 949 cases and 29 788 controls from the Breast Cancer Association Consortium (BCAC).Results: Rs1607237 was significantly associated with a decreased risk of breast cancer in MCBCS, CGEMS and all studies of white Europeans combined (odds ratio (OR)=0.97, 95% confidence interval (CI) 0.95-0.99, P=4.6 × 10(-3)), but did not reach significance in the BCAC replication study alone (OR=0.98, 95% CI 0.96-1.01, P=0.139).Conclusion: Common germline variation in PIK3CA does not have a strong influence on the risk of breast cancer. [ABSTRACT FROM AUTHOR]- Published
- 2011
- Full Text
- View/download PDF
9. Identification of a novel prostate cancer susceptibility variant in the KLK3 gene transcript.
- Author
-
Kote-Jarai, Z., Amin Al Olama, A., Leongamornlert, D., Tymrakiewicz, M., Saunders, E., Guy, M., Giles, G., Severi, G., Southey, M., Hopper, J., Sit, K., Harris, J., Batra, J., Spurdle, A., Clements, J., Hamdy, F., Neal, D., Donovan, J., Muir, K., and Pharoah, P.
- Subjects
PROSTATE cancer ,DISEASE susceptibility ,PROSTATE-specific antigen ,BIOMARKERS ,GENOMES ,RNA splicing ,MOLECULAR dynamics - Abstract
Genome-wide association studies (GWAS) have identified more than 30 prostate cancer (PrCa) susceptibility loci. One of these (rs2735839) is located close to a plausible candidate susceptibility gene, KLK3, which encodes prostate-specific antigen (PSA). PSA is widely used as a biomarker for PrCa detection and disease monitoring. To refine the association between PrCa and variants in this region, we used genotyping data from a two-stage GWAS using samples from the UK and Australia, and the Cancer Genetic Markers of Susceptibility (CGEMS) study. Genotypes were imputed for 197 and 312 single nucleotide polymorphisms (SNPs) from HapMap2 and the 1000 Genome Project, respectively. The most significant association with PrCa was with a previously unidentified SNP, rs17632542 (combined P = 3.9 × 10). This association was confirmed by direct genotyping in three stages of the UK/Australian GWAS, involving 10,405 cases and 10,681 controls (combined P = 1.9 × 10). rs17632542 is also shown to be associated with PSA levels and it is a non-synonymous coding SNP (Ile179Thr) in KLK3. Using molecular dynamic simulation, we showed evidence that this variant has the potential to introduce alterations in the protein or affect RNA splicing. We propose that rs17632542 may directly influence PrCa risk. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
10. Morphological predictors of BRCA1 germline mutations in young women with breast cancer.
- Author
-
Southey, M. C., Ramus, S. J., Dowty, J. G., Smith, L. D., Tesoriero, A. A., Wong, E. E. M., Dite, G. S., Jenkins, M. A., Byrnes, G. B., Winship, I., Phillips, K-A., Giles, G. G., and Hopper, J. L.
- Subjects
BRCA genes ,BREAST cancer ,YOUNG women ,CANCER invasiveness ,TUMOR growth ,CANCER diagnosis ,BREAST tumor diagnosis ,AGE distribution ,ANTHROPOMETRY ,BREAST tumors ,CANCER ,COMPARATIVE studies ,FAMILY health ,RESEARCH methodology ,MEDICAL cooperation ,GENETIC mutation ,PROGNOSIS ,RESEARCH ,RESEARCH funding ,WOMEN ,EVALUATION research ,ACQUISITION of data ,RETROSPECTIVE studies ,GENETIC carriers ,SEQUENCE analysis - Abstract
Background: Knowing a young woman with newly diagnosed breast cancer has a germline BRCA1 mutation informs her clinical management and that of her relatives. We sought an optimal strategy for identifying carriers using family history, breast cancer morphology and hormone receptor status data.Methods: We studied a population-based sample of 452 Australian women with invasive breast cancer diagnosed before age 40 years for whom we conducted extensive germline mutation testing (29 carried a BRCA1 mutation) and a systematic pathology review, and collected three-generational family history and tumour ER and PR status. Predictors of mutation status were identified using multiple logistic regression. Areas under receiver operator characteristic (ROC) curves were estimated using five-fold stratified cross-validation.Results: The probability of being a BRCA1 mutation carrier increased with number of selected histology features even after adjusting for family history and ER and PR status (P<0.0001). From the most parsimonious multivariate model, the odds ratio for being a carrier were: 9.7 (95% confidence interval: 2.6-47.0) for trabecular growth pattern (P=0.001); 7.8 (2.7-25.7) for mitotic index over 50 mitoses per 10 high-powered field (P=0.0003); and 2.7 (1.3-5.9) for each first-degree relative with breast cancer diagnosed before age 60 years (P=0.01).The area under the ROC curve was 0.87 (0.83-0.90).Conclusion: Pathology review, with attention to a few specific morphological features of invasive breast cancers, can identify almost all BRCA1 germline mutation carriers among women with early-onset breast cancer without taking into account family history. [ABSTRACT FROM AUTHOR]- Published
- 2011
- Full Text
- View/download PDF
11. High and low mammographic density human breast tissues maintain histological differential in murine tissue engineering chambers.
- Author
-
Chew, G., Huang, D., Lin, S., Huo, C., Blick, T., Henderson, M., Hill, P., Cawson, J., Morrison, W., Campbell, I., Hopper, J., Southey, M., Haviv, I., and Thompson, E.
- Abstract
Mammographic density (MD) is the area of breast tissue that appears radiologically white on mammography. Although high MD is a strong risk factor for breast cancer, independent of BRCA1/2 mutation status, the molecular basis of high MD and its associated breast cancer risk is poorly understood. MD studies will benefit from an animal model, where hormonal, gene and drug perturbations on MD can be measured in a preclinical context. High and low MD tissues were selectively sampled by stereotactic biopsy from operative specimens of high-risk women undergoing prophylactic mastectomy. The high and low MD tissues were transferred into separate vascularised biochambers in the groins of SCID mice. Chamber material was harvested after 6 weeks for histological analyses and immunohistochemistry for cytokeratins, vimentin and a human-specific mitochondrial antigen. Within-individual analysis was performed in replicate mice, eliminating confounding by age, body mass index and process-related factors, and comparisons were made to the parental human tissue. Maintenance of differential MD post-propagation was assessed radiographically. Immunohistochemical staining confirmed the preservation of human glandular and stromal components in the murine biochambers, with maintenance of radiographic MD differential. Propagated high MD regions had higher stromal ( p = 0.0002) and lower adipose ( p = 0.0006) composition, reflecting the findings in the original human breast tissue, although glands appeared small and non-complex in both high and low MD groups. No significant differences were observed in glandular area ( p = 0.4) or count ( p = 0.4) between high and low MD biochamber tissues. Human mammary glandular and stromal tissues were viably maintained in murine biochambers, with preservation of differential radiographic density and histological features. Our study provides a murine model for future studies into the biomolecular basis of MD as a risk factor for breast cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
12. Increased cancer risks for relatives of very early-onset breast cancer cases with and without BRCA1 and BRCA2 mutations.
- Author
-
Dite, G S, Whittemore, A S, Knight, J A, John, E M, Milne, R L, Andrulis, I L, Southey, M C, McCredie, M R E, Giles, G G, Miron, A, Phipps, A I, West, D W, and Hopper, J L
- Subjects
BREAST cancer risk factors ,GENETIC mutation ,CANCER in women ,DISEASE incidence ,OVARIAN cancer ,LUNG cancer ,PROSTATE cancer ,AGE factors in disease ,BREAST tumors ,SIBLINGS ,FAMILIES ,FAMILY health ,MOTHERS ,RESEARCH funding ,BRCA genes ,RELATIVE medical risk - Abstract
Background: Little is known regarding cancer risks for relatives of women with very early-onset breast cancer.Methods: We studied 2208 parents and siblings of 504 unselected population-based Caucasian women with breast cancer diagnosed before age 35 years (103 from USA, 124 from Canada and 277 from Australia), 41 known to carry a mutation (24 in BRCA1, 16 in BRCA2 and one in both genes). Cancer-specific standardised incidence ratios (SIRs) were estimated by comparing the number of affected relatives (50% verified overall) with that expected based on incidences specific for country, sex, age and year of birth.Results: For relatives of carriers, the female breast cancer SIRs were 13.13 (95% CI 6.57-26.26) and 12.52 (5.21-30.07) for BRCA1 and BRCA2, respectively. The ovarian cancer SIR was 12.38 (3.1-49.51) for BRCA1 and the prostate cancer SIR was 18.55 (4.64-74.17) for BRCA2. For relatives of non-carriers, the SIRs for female breast, prostate, lung, brain and urinary cancers were 4.03 (2.91-5.93), 5.25 (2.50-11.01), 7.73 (4.74-12.62), 5.19 (2.33-11.54) and 4.35 (1.81-10.46), respectively. For non-carriers, the SIRs remained elevated and were statistically significant for breast and prostate cancer when based on verified cancers.Conclusion: First-degree relatives of women with very early-onset breast cancer are at increased risk of cancers not explained by BRCA1 and BRCA2 mutations. [ABSTRACT FROM AUTHOR]- Published
- 2010
- Full Text
- View/download PDF
13. Plasma concentration of Propionibacterium acnes antibodies and prostate cancer risk: results from an Australian population-based case-control study.
- Author
-
Severi, G., Shannon, B. A., Hoang, H. N., Baglietto, L., English, D. R., Hopper, J. L., Pedersen, J., Southey, M. C., Sinclair, R., Cohen, R. J., and Giles, G. G.
- Subjects
PROPIONIBACTERIUM ,PROSTATE cancer risk factors ,IMMUNOGLOBULINS ,HYPERPLASIA ,LOGISTIC regression analysis - Abstract
Background: Recent studies in prostatic tissue suggest that Propionibacterium acnes (P. acnes), a bacterium associated with acne that normally lives on the skin, is the most prevalent bacterium in the prostate and in men with benign prostatic hyperplasia. Its prevalence is higher in samples from patients subsequently diagnosed with prostate cancer. The aim of our study was to test whether circulating levels of P. acnes antibodies are associated with prostate cancer risk and tumour characteristics using plasma samples from a population-based case-control study.Methods: We measured plasma concentration of P. acnes antibodies for 809 cases and 584 controls using a recently developed ELISA assay. We compared antibody titres between cases and controls using unconditional logistic regression adjusted for batch and variables associated with the study design (i.e., age, year of selection and centre). The primary analysis included P. acnes titres in the model as a dichotomous variable using the median value for controls as the cut-off value.Results: P. acnes antibody titres for both cases and controls ranged from 1 : 16 (i.e., low concentration) to 1 : 65,536 (i.e., high concentration; median value=1 : 1024). The odds ratio for prostate cancer associated with titres at or above the median value was 0.73 (95% CI 0.58-0.91, P=0.005). The association appeared to be particularly strong for advanced prostate cancer (AJCC Stage grouping III-IV) for which the odds ratio was 0.59 (95% CI 0.43-0.81, P=0.001) but there was insufficient evidence that the association differed by tumour stage (p heterogeneity=0.07).Conclusion: These results need to be confirmed in prospective studies but they are consistent with the hypothesis that P. acnes has a role in prostate cancer. [ABSTRACT FROM AUTHOR]- Published
- 2010
- Full Text
- View/download PDF
14. Sibship analysis of associations between SNP haplotypes and a continuous trait with application to mammographic density.
- Author
-
Stone, J., Gurrin, L. C., Hayes, V. M., Southey, M. C., Hopper, J. L., and Byrnes, G. B.
- Published
- 2010
- Full Text
- View/download PDF
15. The role of SMAD4 in early-onset colorectal cancer.
- Author
-
Royce, S. G., Alsop, K., Haydon, A., Mead, L., Smith, L. D., Tesoriero, A. A., Giles, G. G., Jenkins, M. A., Hopper, J. L., and Southey, M. C.
- Subjects
COLON cancer ,ANAL cancer ,TUMOR growth ,DNA damage ,MUTAGENESIS ,GENE expression ,CANCER patients - Abstract
Objective Chromosomal loss within the region of 18q and loss of SMAD4 expression have been reported to be frequent somatic events during colorectal cancer tumour progression; however, their associations with age at onset have not been widely studied. Method We analysed 109 tumours from a population-based case-family study based on colorectal cancers diagnosed before the age of 45 years. These patients with early-onset colorectal cancer had been previously screened for germ-line mismatch repair gene mutations, microsatellite instability (that included the mononucleotide repeat in TGFβRII) and somatic k-ras mutations. We measured SMAD4 protein expression using immunohistochemistry and SMAD4 copy number using quantitative real-time PCR. Results Loss of SMAD4 protein expression was observed in 27/109 (25%) of cancers tested and was more commonly observed in rectal tumours (15/41, 36%) when compared with tumours arising in the colon (11/66, 17%) ( P = 0.04). There was no association between SMAD4 protein expression and TGFβR11 mutation status, SMAD4 copy number, family history, MSI status, tumour stage or grade. Conclusion Loss of SMAD4 expression is a common feature of early-onset colorectal tumours as it is in colorectal cancers diagnosed in other age-groups. Taken together, the molecular pathways (genetic and epigenetic) now known to be involved in early-onset colorectal cancer only explain a small proportion of the disease and require further exploration. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
16. The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions.
- Author
-
Antoniou, A. C., Cunningham, A. P., Peto, J., Evans, D. G., Lalloo, F., Narod, S. A., Risch, H. A., Eyfjord, J. E., Hopper, J. L., Southey, M. C., Olsson, H., Johannsson, O., Borg, A., Passini, B., Radice, P., Manoukian, S., Eccles, D. M., Tang, N., Olah, E., and Anton-Culver, H.
- Subjects
CANCER susceptibility ,CANCER in women ,BREAST cancer ,MALE reproductive organs ,CANCER patients ,DRUG therapy ,AGE distribution ,BIOLOGICAL models ,BREAST tumors ,COMPARATIVE studies ,DISEASE susceptibility ,GENETIC techniques ,RESEARCH methodology ,MEDICAL cooperation ,GENETIC mutation ,OVARIAN tumors ,RESEARCH ,RESEARCH funding ,EVALUATION research ,BRCA genes ,SECONDARY primary cancer - Abstract
Multiple genetic loci confer susceptibility to breast and ovarian cancers. We have previously developed a model (BOADICEA) under which susceptibility to breast cancer is explained by mutations in BRCA1 and BRCA2, as well as by the joint multiplicative effects of many genes (polygenic component). We have now updated BOADICEA using additional family data from two UK population-based studies of breast cancer and family data from BRCA1 and BRCA2 carriers identified by 22 population-based studies of breast or ovarian cancer. The combined data set includes 2785 families (301 BRCA1 positive and 236 BRCA2 positive). Incidences were smoothed using locally weighted regression techniques to avoid large variations between adjacent intervals. A birth cohort effect on the cancer risks was implemented, whereby each individual was assumed to develop cancer according to calendar period-specific incidences. The fitted model predicts that the average breast cancer risks in carriers increase in more recent birth cohorts. For example, the average cumulative breast cancer risk to age 70 years among BRCA1 carriers is 50% for women born in 1920-1929 and 58% among women born after 1950. The model was further extended to take into account the risks of male breast, prostate and pancreatic cancer, and to allow for the risk of multiple cancers. BOADICEA can be used to predict carrier probabilities and cancer risks to individuals with any family history, and has been implemented in a user-friendly Web-based program (http://www.srl.cam.ac.uk/genepi/boadicea/boadicea_home.html). [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
17. Validation study of thelambda model for predicting the BRCA1 or BRCA2 mutation carrier status of North American Ashkenazi Jewish women.
- Author
-
Apicella, C., Dowty, J. G., Dite, G. S., Jenkins, M. A., Senie, R. T., Daly, M. B., Andrulis, I. L., John, E. M., Buys, S. S., Li, F. P., Glendon, G., Chung, W., Ozcelik, H., Miron, A., Kotar, K., Southey, M. C., Foulkes, W. D., and Hopper, J. L.
- Subjects
BREAST cancer ,GENETIC disorders ,GENETICS ,CLINICAL medicine ,GENETIC mutation - Abstract
lambda is a model that estimates the probability an Ashkenazi Jewish (AJ) woman carries an ancestral BRCA1 or BRCA2 mutation from her personal and family cancer history.lambda is relevant to clinical practice, and its implementation does not require a computer. It was developed principally from Australian and UK data. We conducted a validation study using 1286 North American AJ women tested for the mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2. Most had a personal or family history of breast cancer. We observed 197 carriers. The area under the receiver operator characteristic (ROC) curve (a measure of ranking) was 0.79 [95% confidence interval (CI) = 0.77–0.81], similar to that for the model-generating data (0.78; 95% CI = 0.75–0.82).lambda predicted 232 carriers (18% more than observed; p = 0.002) and was overdispersed (p = 0.009). The Bayesian computer programbrcapro gave a similar area under the ROC curve (0.78; 95% CI = 0.76–0.80), but predicted 367 carriers (86% more than observed; p < 0.0001), and was substantially overdispersed (p < 0.0001). Therefore,lambda is comparable tobrcapro for ranking AJ women according to their probability of being a BRCA1 or BRCA2 mutation carrier and is more accurate thanbrcapro which substantially overpredicts carriers in this population. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
18. Cytomegalovirus, Epstein-Barr virus and risk of breast cancer before age 40 years: a case-control study.
- Author
-
Richardson, A. K., Cox, B., McCredie, M. R. E., Dite, G. S., Chang, J. -H., Gertig, D. M., Southey, M. C., Giles, G. G., and Hopper, J. I.
- Subjects
ETIOLOGY of diseases ,EPIDEMIOLOGY ,PUBLIC health ,BREAST cancer ,CYTOMEGALOVIRUS diseases ,EPSTEIN-Barr virus - Abstract
We investigated whether there is an association between cytomegalovirus (CMV) and Epstein-Barr virus (EBV) IgG levels and risk of breast cancer before age 40 years. CMV and EBV IgG levels were measured in stored plasma from 208 women with breast cancer and 169 controls who participated in the Australian Breast Cancer Family Study (ABCFS), a population-based case-control study. CMV and EBV IgG values were measured in units of optical density (OD). Cases and controls did not differ in seropositivity for CMV (59 and 57% respectively; P=0.8) or EBV (97 and 96% respectively; P=0.7). In seropositive women, mean IgG values were higher in cases than controls for CMV (1.20 vs 0.98 OD, P=0.005) but not for EBV (2.65 vs 2.57 OD, P=0.5). The adjusted odds ratios per OD unit were 1.46 (95% CI 1.06-2.03) for CMV IgG and 1.11 (0.93-1.33) for EBV IgG. The higher mean CMV IgG levels found in women with breast cancer could be the result of a more recent infection with CMV, and may mean that late exposure to CMV is a risk factor for breast cancer.British Journal of Cancer (2004) 90, 2149-2152. doi:10.1038/sj.bjc.6601822 www.bjcancer.com Published online 20 April 2004 [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
19. CYP17 promoter polymorphism and breast cancer in Australian women under age forty years.
- Author
-
Spurdle, Amanda B., Hopper, John L., Spurdle, A B, Hopper, J L, Dite, G S, Chen, X, Cui, J, McCredie, M R, Giles, G G, Southey, M C, Venter, D J, Easton, D F, and Chenevix-Trench, G
- Subjects
CANCER genetics ,CANCER in women ,PROMOTERS (Genetics) ,DNA analysis ,AGE distribution ,AGE factors in disease ,ALLELES ,BREAST tumors ,COMPARATIVE studies ,DNA probes ,GENES ,GENETIC polymorphisms ,RESEARCH methodology ,MEDICAL cooperation ,GENETIC mutation ,ONCOGENES ,OXIDOREDUCTASES ,POLYMERASE chain reaction ,RESEARCH ,LOGISTIC regression analysis ,EVALUATION research ,BRCA genes ,RELATIVE medical risk ,CASE-control method ,GENOTYPES - Abstract
Background: The cytochrome P450c17alpha enzyme functions in the steroid biosynthesis pathway, and altered endogenous steroid hormone levels have been reported to be associated with a T to C polymorphism in the 5' promoter region of the CYP17 gene. Because steroid hormone exposure is known to influence breast cancer risk, we conducted a population-based, case-control-family study to assess the relationship between the CYP17 promoter polymorphism and early-onset breast cancer.Methods: Case subjects under 40 years of age at diagnosis of a first primary breast cancer, population-sampled control subjects, and the relatives of both case and control subjects were interviewed to record family history of breast cancer and other risk factors. CYP17 genotype was determined in 369 case subjects, 284 control subjects, and 91 relatives of case subjects. Genotype distributions were compared by logistic regression, and cumulative risk was estimated by a modified segregation analysis. All statistical tests were two-tailed.Results: Compared with the TT genotype (i.e., individuals homozygous for the T allele), the TC genotype was not associated with increased breast cancer risk (P: =.7). Compared with the TT and TC genotypes combined, the CC genotype was associated with a relative risk of 1. 81 (95% confidence interval [CI] = 1.15-2.86; P: =.01) before adjustment for measured risk factors and 1.63 (95% CI = 1.00-2.64; P: =.05) after adjustment. There was an excess of CC genotypes in case subjects who had at least one affected first- or second-degree relative, compared with control subjects unstratified by family history of breast cancer (23% versus 11%; P: =.006), and these case subjects had a threefold to fourfold higher risk than women of other groups defined by genotype and family history of breast cancer. Analysis of breast cancer in first- and second-degree relatives of case subjects with the CC genotype, excluding two known carriers of a deleterious mutation in BRCA1 or BRCA2, gave a relative hazard in women with the CC genotype of 3.48 (95% CI = 1.13-10.74; P: =.04), which is equivalent to a cumulative risk of 16% to age 70 years.Conclusions: The CC genotype may modify the effect of other familial risk factors for early-onset breast cancer. [ABSTRACT FROM AUTHOR]- Published
- 2000
- Full Text
- View/download PDF
20. BRCA1 mutations and other sequence variants in a population-based sample of Australian women with breast cancer.
- Author
-
Southey, M C, Tesoriero, A A, Andersen, C R, Jennings, K M, Brown, S M, Dite, G S, Jenkins, M A, Osborne, R H, Maskiell, J A, Porter, L, Giles, G G, McCredie, M R E, Hopper, J L, and Venter, D J
- Subjects
BREAST cancer ,GENETIC mutation - Abstract
The frequency, in women with breast cancer, of mutations and other variants in the susceptibility gene, BRCA1, was investigated using a population-based case-control-family study. Cases were women living in Melbourne or Sydney, Australia, with histologically confirmed, first primary, invasive breast cancer, diagnosed before the age of 40 years, recorded on the state Cancer Registries. Controls were women without breast cancer, frequency-matched for age, randomly selected from electoral rolls. Full manual sequencing of the coding region ofBRCA1 was conducted in a randomly stratified sample of 91 cases; 47 with, and 44 without, a family history of breast cancer in a first- or second-degree relative. All detected variants were tested in a random sample of 67 controls. Three cases with a (protein-truncating) mutation were detected. Only one case had a family history; her mother had breast cancer, but did not carry the mutation. The proportion of Australian women with breast cancer before age 40 who carry a germline mutation inBRCA1 was estimated to be 3.8% (95% Cl 0.3-12.6%). Seven rare variants were also detected, but for none was there evidence of a strong effect on breast cancer susceptibility. Therefore, on a population basis, rare variants are likely to contribute little to breast cancer incidence. [ABSTRACT FROM AUTHOR]
- Published
- 1999
- Full Text
- View/download PDF
21. HRAS1 rare minisatellite alleles and breast cancer in Australian women under age forty years.
- Author
-
Firgaira, Frank A., Seshadri, Ram, Firgaira, F A, Seshadri, R, McEvoy, C R, Dite, G S, Giles, G G, McCredie, M R, Southey, M C, Venter, D J, and Hopper, J L
- Subjects
NUCLEOTIDE sequence ,ALLELES ,BREAST cancer ,BREAST tumors ,COMPARATIVE studies ,GENOMES ,RESEARCH methodology ,MEDICAL cooperation ,PROTEINS ,RESEARCH ,STATISTICAL sampling ,EVALUATION research ,CASE-control method ,ODDS ratio - Abstract
Background: A recent meta-analysis of 23 studies supported the empirically derived hypothesis that women who lack one of the four common minisatellite alleles at the HRAS1 locus are at increased risk of breast cancer. These studies relied on visual sizing of alleles on electrophoretic gels and may have underreported rare alleles. We determined whether this hypothesis applied to early-onset breast cancer by using a new method to size minisatellite alleles.Methods: We conducted a population-based, case-control-family study of 249 Australian women under 40 years old at diagnosis of a first primary breast cancer and 234 randomly selected women, frequency matched for age. We sized HRAS1 minisatellite alleles with an Applied Biosystems model 373 automated DNA sequencer and GENESCAN(TM) software. All P values are two-sided.Results: We found no association of rare alleles with breast cancer, before or after adjustment for risk factors and irrespective of how their effects were modeled (crude odds ratio = 1.04; 95% confidence interval [CI] = 0.071-1.53; P =.8). The rare allele frequency was 0. 173 (95% CI = 0.149-0.197), three times the pooled estimate of 0.058 (95% CI = 0.050-0.066) from previous studies (P<.001), and was similar for case subjects, 0.177 (95% CI = 0.143-0.221), and control subjects, 0.169 (95% CI = 0.135-0.203) (P =.7).Conclusion: There was no support for an association between rare HRAS1 alleles and the risk of early-onset breast cancer, despite 80% power to detect effects of the magnitude of those associations (1.7-fold) previously suggested.Implications: The question of whether cancer risk is associated with rare minisatellite HRAS1 alleles needs to be revisited with the use of new methods that have a greater ability to distinguish rare alleles from similarly sized common alleles. [ABSTRACT FROM AUTHOR]- Published
- 1999
- Full Text
- View/download PDF
22. Androgen receptor exon 1 CAG repeat length and breast cancer in women before age forty years.
- Author
-
Spurdle, Amanda B., Dite, Gillian S., Chen, Xiaoqing, Mayne, Carol J., Southey, Melissa C., Batten, Leigh E., Chy, Hun, Trute, Lynne, McCredie, Margaret R. E., Giles, Graham G., Armes, Jane, Venter, Deon J., Hopper, John L., Chenevix-Trench, Georgia, Spurdle, A B, Dite, G S, Chen, X, Mayne, C J, Southey, M C, and Batten, L E
- Subjects
ANDROGENS ,BREAST cancer ,AGE factors in disease ,BREAST tumors ,CELL receptors ,COMPARATIVE studies ,DNA ,GENES ,GENETIC polymorphisms ,IMMUNOHISTOCHEMISTRY ,RESEARCH methodology ,MEDICAL cooperation ,REGRESSION analysis ,RESEARCH ,LOGISTIC regression analysis ,EVALUATION research ,CASE-control method ,ODDS ratio ,GENOTYPES - Abstract
Background: We conducted a population-based, case-control-family study to determine whether androgen receptor (AR) exon 1 polymorphic CAG repeat length (CAGn) was a risk factor for early-onset breast cancer in the Australian population.Methods: Case subjects under 40 years of age at diagnosis of a first primary breast cancer and age-matched control subjects were interviewed to assess family history and other risk factors. AR CAGn length was determined for 368 case subjects and 284 control subjects. Distributions in the two groups were compared by linear and logistic regression, allowing adjustment for measured risk factors. All statistical tests were two-tailed.Results: When analyzed as either a continuous or a dichotomous variable, there was no association between CAG, length and breast cancer risk, before or after adjustment for risk factors. Mean (95% confidence interval [CI]) CAGn lengths were 22.0 (21.8-22.2) for case subjects and 22.0 (21.7-22.3) for control subjects (P = .9). The frequency (95% CI) of alleles with 22 or more CAGn repeats was 0.531 (0.494-0.568) for case subjects and 0.507 (0.465-0.549) for control subjects (P = .4). After adjustment, the average effect on log OR (odds ratio) per allele was 0.16 (95% CI = -0.03 to 0.40; P = .2), and the effect of any allele was equivalent to an OR of 1.40 (95% CI = 0.94-2.09; P = .1). Stratification by family history also failed to reveal any association. Similar results were obtained when alleles were defined by other cutoff points.Conclusion: We found no evidence for an association between AR exon 1 CAGn length and breast cancer risk in women under the age of 40, despite having 80% power to detect modest effects. [ABSTRACT FROM AUTHOR]- Published
- 1999
- Full Text
- View/download PDF
23. Estrogen receptor polymorphism at codon 325 and risk of breast cancer in women before age forty.
- Author
-
Southey, M C, Batten, L E, McCredie, M R, Giles, G G, Dite, G, Hopper, J L, and Venter, D J
- Subjects
ALLELES ,BREAST tumors ,COMPARATIVE studies ,DNA probes ,GENES ,GENETIC polymorphisms ,RESEARCH methodology ,MEDICAL cooperation ,PROTEINS ,RESEARCH ,EVALUATION research ,CASE-control method ,ODDS ratio - Abstract
Background: The estrogen receptor (ER) protein is believed to play a role in the development and progression of breast cancer. In a previously published U.S. clinic-based study, a polymorphism in the ER gene (codon 325, CCC --> CCG) was found to be more common in 34 case subjects with a family history of breast cancer than in 154 case subjects without such a history (mean allele frequencies +/- standard error = 0.28+/-0.05 versus 0.11+/-0.02; P<.001). To determine whether this polymorphism is a risk factor for early-onset breast cancer, we conducted a population-based, case-control-family study in Australia.Methods: Case subjects under the age of 40 years with a first primary breast cancer and control subjects, frequency-matched to the case subjects on the basis of age, and their relatives were interviewed to assess the family history of breast cancer. Polymorphism status of the ER gene was determined for 388 case subjects and 294 control subjects. All statistical tests were two-tailed.Results: There was no association between ER gene polymorphism status and breast cancer, before or after adjustment for risk factors. There was no difference in allele frequencies between case subjects and control subjects (0.232+/-0.015 versus 0.209+/-0.017; P = .4) or between women with and without a family history of breast cancer (P = .3), irrespective of case-control status. The findings were not altered when different definitions of family history of breast cancer were used and when allele frequencies were adjusted for residence and country of birth.Conclusion: We found no evidence that the ER codon 325 polymorphism is associated with breast cancer before the age of 40 years or with a family history of breast cancer, despite ample power to detect effects half the magnitude of those previously reported. [ABSTRACT FROM AUTHOR]- Published
- 1998
- Full Text
- View/download PDF
24. Lymphoproliferative disease of donor origin arising in patients after orthotopic liver transplantation.
- Author
-
Armes, Jane E., Angus, Peter, Soufhey, Melissa C., Battaglia, Samuel E., Ross, Bruce C., Jones, Robert M., Venter, Deon J., Armes, J E, Angus, P, Southey, M C, Battaglia, S E, Ross, B C, Jones, R M, and Venter, D J
- Published
- 1994
- Full Text
- View/download PDF
25. Are PALB2 mutations associated with increased risk of male breast cancer?
- Author
-
Sauty de Chalon, A., Teo, Z., Park, D., Odefrey, F., Hopper, J., and Southey, M.
- Published
- 2010
- Full Text
- View/download PDF
26. Large genomic alterations in hMSH2 and hMLH1 in early-onset colorectal cancer: identification of a large complex de novo hMLH1 alteration.
- Author
-
Smith, L., Tesoriero, A., Mead, L., Royce, S., Grubb, G., Young, J., Giles, G., Jenkins, M., Macrae, F., Hopper, J. L., and Southey, M. C.
- Subjects
LETTERS to the editor ,GENOMICS - Abstract
A letter to the editor is presented offering important information regarding the medical study focusing on the large genomic alterations on human proteins in early-onset colorectal cancer.
- Published
- 2006
- Full Text
- View/download PDF
27. Correction: Evaluation of water displacement energetics in protein binding sites with grid cell theory.
- Author
-
Gerogiokas, G., Southey, M. W. Y., Mazanetz, M. P., Hefeitz, A., Bodkin, M., Law, R. J., and Michel, J.
- Abstract
Correction for ‘Evaluation of water displacement energetics in protein binding sites with grid cell theory’ by G. Gerogiokas et al., Phys. Chem. Chem. Phys., 2015, 17, 8416–8426. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
28. Molecular Characterization and Cancer Risk Associated with BRCA1 and BRCA2 Splice Site Variants Identified in Multiple-Case Breast Cancer Families.
- Author
-
Tesoriero, A. A., Wong, E. M., Jenkins, M. A., Hopper, J. L., Brown, M. A., Chenevix‐Trench, G., Spurdle, A. B., and Southey, M. C.
- Published
- 2014
- Full Text
- View/download PDF
29. The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions.
- Author
-
Antoniou, A C, Cunningham, A P, Peto, J, Evans, D G, Lalloo, F, Narod, S A, Risch, H A, Eyfjord, J E, Hopper, J L, Southey, M C, Olsson, H, Johannsson, O, Borg, A, Pasini, B, Radice, P, Manoukian, S, Eccles, D M, Tang, N, Olah, E, and Anton-Culver, H
- Subjects
BREAST cancer - Abstract
A correction to the article "The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions" that was published in the 2008 issue is presented.
- Published
- 2008
- Full Text
- View/download PDF
30. Molecular characterization and cancer risk associated with BRCA1 and BRCA2 splice site variants identified in multiple-case breast cancer families.
- Author
-
Tesoriero, A. A., Wong, E. M., Jenkins, M. A., Hopper, J. L., kConFab, Brown, M. A., Chenevix-Trench, G., Spurdle, A. B., and Southey, M. C.
- Abstract
Genetic screening of women from multiple-case breast cancer families and other research-based endeavors have identified an extensive collection of germline variations of BRCA1 and BRCA2 that can be classified as deleterious and have clinical relevance. For some variants, such as those in the conserved intronic splice site regions which are highly likely to alter splicing, it is not possible to classify them based on the identified DNA sequence variation alone. We studied 11 multiple-case breast cancer families carrying seven distinct splice site region genetic alterations in BRCA1 or BRCA2 ( BRCA1, c. IVS6-2delA, c.IVS9-2A>C, c.IVS4-1G>T, c.IVS20+1G>A and BRCA2, c.IVS17-1G>C, c.IVS20+1G>A, c.IVS7-1G>A) and applied SpliceSiteFinder to predict possible changes in efficiency of splice donor and acceptor sites, characterized the transcripts, and estimated the average age-specific cumulative risk (penetrance) using a modified segregation analysis. SpliceSiteFinder predicted and we identified transcipts that illustrated that all variants caused exon skipping, and all but two led to frameshifts. The risks of breast cancer to age 70 yrs, averaged over all variants, over BRCA1 variants alone, and over BRCA2 variants alone, were 73% (95% confidence interval 47-93), 64% (95%CI 28-96) and 79% (95%CI 48-98) respectively (all P<0.0001). Therefore five of these seven consensus splice site variants of BRCA1 and BRCA2 produce a transcript similar to that of other previously described deleterious exonic variants and are associated with similar high lifetime risks. © 2005 Wiley-Liss, Inc. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.